Recent developments include the completion of the Electrochem acquisition and financing, quarterly revenue growth, and insider share purchases.

• Ultralife completed the acquisition of Electrochem Solutions, Inc. and secured financing related to this transaction in early 2026 [N1].
• The company reported a 13% increase in Q2 2025 revenue, reflecting growth in its business segments [N2].
• Ultralife held a Q2 2025 earnings call providing detailed operational and financial updates [N3].
• Quarterly earnings reports in 2025 showed revenue growth alongside some profit decreases [N4][N5][N6].
• Insider purchases of shares were reported in mid-2025, indicating insider confidence [N1].

Ultralife’s recent acquisition of Electrochem Solutions and secured financing enhance its product offerings and market reach. The company demonstrated revenue growth in recent quarters, including a 21% increase in Q1 2025 and a 13% rise in Q2 2025, indicating positive business momentum. Experienced leadership and a strong governance framework support operational execution and strategic initiatives. Insider purchases in 2025 may reflect confidence in the company’s prospects.

Despite revenue growth, Ultralife reported a net loss for the full year 2025 and experienced profit decreases in some quarters, indicating challenges in profitability. The company carries significant long-term debt with scheduled repayments through 2029, which may impact financial flexibility. Market exposure to both commercial and government/defense sectors subjects the company to potential fluctuations in demand and government spending. Integration risks related to recent acquisitions and competitive pressures in battery and communications markets may affect performance.

Ultralife’s moat is supported by its specialized expertise in battery technology, including patented lithium-ion polymer cells, and its established presence in both commercial and government/defense markets. The company’s long-standing industry experience, product innovation, and strategic acquisitions such as Electrochem Solutions contribute to its competitive positioning. Its relationships with government and defense customers, along with proprietary technology, create barriers to entry for competitors.

• Profitability Challenges: Ultralife reported a net loss of approximately $5.9 million for the fiscal year 2025, with some quarterly profit decreases, indicating ongoing challenges in achieving consistent profitability.
• Debt Obligations: The company has a senior secured term loan facility with outstanding principal around $50.9 million as of September 30, 2025, requiring scheduled repayments through 2029, which may constrain financial flexibility.
• Market and Customer Concentration: Ultralife serves both commercial and government/defense markets, exposing it to demand variability and potential changes in government spending priorities.
• Acquisition Integration: The recent acquisition of Electrochem Solutions introduces integration risks, including operational, financial, and cultural challenges that could affect business performance.

• Ultralife Corporation is a Delaware corporation headquartered in Newark, New York, operating in battery and communications systems products.
• The company operates primarily in two segments: Communications Systems and Battery & Energy Products.
• Its customer base includes both commercial and government/defense markets.
• Ultralife completed the acquisition of Electrochem Solutions, Inc. and secured financing related to this acquisition as of early 2026.
• The company reported full-year 2025 revenue of approximately $191.2 million and a net loss of about $5.9 million, with basic and diluted EPS of -$35 per share as of December 31, 2025.
• Liquidity ratios as of December 31, 2025 include a current ratio of 2.83 and a cash ratio of 0.25, with cash and equivalents of approximately $9.3 million and current assets of about $105.8 million against current liabilities of $37.3 million.
• Ultralife has a senior secured term loan facility of $55 million with scheduled repayments through 2029, with outstanding principal around $50.9 million as of September 30, 2025, and no outstanding revolving credit facility balance.
• The company’s board includes experienced executives with expertise in battery technology, manufacturing, finance, and corporate governance.
• Recent quarterly results showed revenue growth, including a 13% increase in Q2 2025 revenue and 21% revenue growth in Q1 2025, alongside profit decreases in some quarters.
• Ultralife’s governance structure separates the roles of CEO and Board Chair, with most directors independent under NASDAQ standards.
• The company’s financial statements and disclosures are current as of early 2026, including an amended 10-K filing and quarterly 10-Q filings.
• Insider purchases of shares were reported in mid-2025, indicating some insider confidence.
• The company’s product portfolio addresses both commercial and defense markets, with a focus on battery and communications systems products.